Satellos Bioscience Inc. (MSCLF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Satellos Bioscience Inc. (MSCLF) trades at $6.25 with AI Score 52/100 (Grade B). Satellos Bioscience Inc. is a regenerative medicine company focused on developing therapeutics for degenerative muscle diseases. Market cap: $96.62M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for MSCLF: MSCLF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MSCLF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
MSCLF: 3/7 perspectives are bearish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Satellos Bioscience Inc. (MSCLF) Healthcare & Pipeline Overview
Satellos Bioscience Inc. is a regenerative medicine company specializing in therapeutics for degenerative muscle diseases, primarily focusing on correcting muscle stem cell polarity to enhance natural muscle repair. Their lead program is an oral therapeutic drug, positioning them within the biotechnology sector with a focus on innovative regenerative solutions.
What Is the Investment Thesis for MSCLF?
Satellos Bioscience Inc. presents a speculative investment opportunity within the regenerative medicine sector. The company's focus on correcting muscle stem cell polarity offers a novel approach to treating degenerative muscle diseases. A key value driver is the successful development and clinical validation of their lead oral therapeutic drug. Upcoming milestones include preclinical and clinical trial results, which will significantly impact the company's valuation. However, the company's OTC listing and limited financial information pose substantial risks. The company's market capitalization is $0.12B and P/E ratio is -1.76. Positive clinical data could drive significant upside, while setbacks could lead to substantial losses. Investors should carefully consider the high-risk, high-reward nature of this investment.
Based on FMP financials and quantitative analysis
MSCLF Key Highlights
- Satellos Bioscience Inc. is focused on regenerative medicine, specifically developing therapeutics for degenerative muscle diseases.
- The company's lead program involves an oral therapeutic drug designed to correct muscle stem cell polarity.
- Satellos's approach aims to restore the body's innate muscle repair and regeneration process.
- Incorporated in 2012, Satellos is headquartered in Toronto, Canada.
- The company's market capitalization is $0.12B with a P/E ratio of -1.76.
Who Are MSCLF's Competitors?
MSCLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BSEM BioStem Technologies, Inc. | $3.66 | +12.96% | $62.16M | 61 |
| IUGNF Imugene Limited | $0.06 | -25.00% | $24.95M | 41 |
| KNTPF Kintor Pharmaceutical Limited | $0.25 | +0.00% | $115.49M | 56 |
| PBIGF Paradigm Biopharmaceuticals Limited | $0.15 | +0.00% | $65.01M | 41 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MSCLF's Key Strengths?
- Novel approach to treating degenerative muscle diseases.
- Focus on oral therapeutic drugs for convenient administration.
- Strong expertise in regenerative medicine.
- Potential for significant market opportunity in muscle regeneration.
What Are MSCLF's Weaknesses?
- Limited financial resources.
- Early stage of development with no approved products.
- Reliance on a single lead program.
- OTC market listing presents liquidity and regulatory challenges.
What Could Drive MSCLF Stock Higher?
- Preclinical data release for lead oral therapeutic drug program.
- Initiation of Phase 1 clinical trials for lead program.
- Strategic partnerships and collaborations with pharmaceutical companies.
- Expansion of therapeutic pipeline to address other degenerative diseases.
- Potential for orphan drug designation for rare muscle diseases.
What Are the Key Risks for MSCLF?
- Negative return on equity (-51.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures and regulatory setbacks.
- Competition from larger biotechnology and pharmaceutical companies.
- Patent challenges and intellectual property disputes.
- Limited financial resources and reliance on external funding.
- OTC market listing presents liquidity and regulatory challenges.
What Are the Growth Opportunities for MSCLF?
- Expansion of Therapeutic Pipeline: Satellos has the opportunity to expand its therapeutic pipeline beyond its lead program. By identifying and developing additional therapies targeting different aspects of muscle regeneration or other degenerative diseases, the company can diversify its revenue streams and reduce its reliance on a single product. This expansion could involve internal research and development efforts, as well as strategic collaborations or acquisitions of other companies or technologies. The market for regenerative medicine is projected to reach billions of dollars in the coming years.
- Strategic Partnerships and Collaborations: Satellos can pursue strategic partnerships and collaborations with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its therapies. These partnerships can provide access to funding, expertise, and distribution networks, which can significantly enhance Satellos's ability to bring its products to market. Collaborations with research institutions can also facilitate access to cutting-edge technologies and scientific expertise, further accelerating the company's research and development efforts. Timeline for partnerships is ongoing.
- Geographic Expansion: Satellos can expand its geographic reach beyond its current base in Canada. By entering new markets, such as the United States, Europe, and Asia, the company can tap into larger patient populations and increase its revenue potential. Geographic expansion may involve establishing local offices, partnering with distributors, or licensing its technologies to companies in other countries. The timeline for geographic expansion is dependent on regulatory approvals and market access strategies in each target region.
- Advancements in Delivery Technologies: Satellos can invest in the development of advanced drug delivery technologies to improve the efficacy and safety of its therapies. These technologies may include targeted drug delivery systems, controlled-release formulations, and non-invasive delivery methods. By improving the way its therapies are delivered to the body, Satellos can enhance their therapeutic effects and reduce the risk of side effects. The market for drug delivery technologies is experiencing rapid growth, driven by the increasing demand for more effective and patient-friendly therapies. Timeline for advancements is ongoing.
- Orphan Drug Designation: Satellos could pursue orphan drug designation for its therapies targeting rare degenerative muscle diseases. Orphan drug designation provides several benefits, including market exclusivity, tax credits for clinical trials, and waivers of certain regulatory fees. These incentives can significantly reduce the cost and risk associated with developing therapies for rare diseases, making it more attractive for companies like Satellos to invest in these areas. The FDA grants orphan drug designation to encourage the development of therapies for diseases affecting fewer than 200,000 people in the United States.
What Opportunities Does MSCLF Have?
- Strategic partnerships with larger pharmaceutical companies.
- Expansion of therapeutic pipeline to address other degenerative diseases.
- Advancements in drug delivery technologies.
- Orphan drug designation for rare muscle diseases.
What Threats Does MSCLF Face?
- Competition from larger biotechnology and pharmaceutical companies.
- Regulatory hurdles and clinical trial failures.
- Patent challenges and intellectual property disputes.
- Economic downturn and reduced investor interest in biotechnology.
What Are MSCLF's Competitive Advantages?
- Proprietary technology related to muscle stem cell polarity correction.
- Patent protection for its therapeutic drugs.
- Expertise in regenerative medicine and muscle biology.
- First-mover advantage in targeting a specific mechanism of muscle regeneration.
What Does MSCLF Do?
Satellos Bioscience Inc., established in 2012 and headquartered in Toronto, Canada, is a biotechnology company dedicated to regenerative medicine. The company focuses on developing innovative therapeutics to address degenerative muscle diseases. Satellos's core mission revolves around harnessing the body's innate ability to repair and regenerate muscle tissue. Their primary program centers on an oral therapeutic drug designed to correct muscle stem cell polarity, a critical factor in effective muscle regeneration. By targeting this fundamental mechanism, Satellos aims to restore the natural muscle repair process, offering a potential solution for conditions characterized by muscle degeneration. Satellos operates within the biotechnology sector, concentrating on regenerative medicine approaches to combat muscle-related disorders. Their research and development efforts are geared towards creating novel therapies that can significantly improve the lives of individuals affected by these debilitating conditions. The company's focus on oral therapeutics provides a convenient and potentially more accessible treatment option for patients.
What Products and Services Does MSCLF Offer?
- Develop therapeutics for degenerative muscle diseases.
- Focus on regenerative medicine approaches.
- Research and develop oral therapeutic drugs.
- Target muscle stem cell polarity.
- Restore the body's innate muscle repair process.
- Conduct preclinical and clinical trials.
How Does MSCLF Make Money?
- Develop and patent novel therapeutic drugs.
- Conduct research and development activities.
- Seek regulatory approvals for its therapies.
- Commercialize its products through partnerships or direct sales.
What Industry Does MSCLF Operate In?
Satellos Bioscience Inc. operates within the rapidly evolving biotechnology industry, specifically targeting the regenerative medicine sub-sector. This area focuses on developing therapies that can repair or replace damaged tissues and organs. The market for regenerative medicine is projected to experience substantial growth, driven by an aging population and increasing prevalence of chronic diseases. Satellos faces competition from other biotechnology companies, including BSEM, HSCHF, IUGNF, KNTPF, and PBIGF, some of which may have greater resources and more advanced technologies. Success in this industry requires significant investment in research and development, as well as navigating complex regulatory pathways.
Who Are MSCLF's Key Customers?
- Patients with degenerative muscle diseases.
- Healthcare providers who treat these patients.
- Pharmaceutical companies interested in licensing or acquiring Satellos's therapies.
ROE -51%Key Financial Metrics
Return on equity for Satellos Bioscience Inc. stands at -51.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -25.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -23.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 11.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -56.7%, the inverse of the P/E and a quick read on earnings relative to price.
Satellos Bioscience Inc. (MSCLF) Valuation Context
Valued at $96.62M, MSCLF is classified as a micro-cap stock. Relative to its peer group, MSCLF's quantitative score of 52/100 is roughly in line with the peer average of 56/100.
Company Profile
Satellos Bioscience Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Francis Gleeson. MSCLF has traded publicly since 2012.
F-Score 1/9Financial Health
Satellos Bioscience Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 9.23 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Satellos Bioscience Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.15.
MSCLF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Novel approach to treating degenerative muscle diseases.
- Focus on oral therapeutic drugs for convenient administration.
- Strong expertise in regenerative medicine.
- Potential for significant market opportunity in muscle regeneration.
Bear Case
- Limited financial resources.
- Early stage of development with no approved products.
- Reliance on a single lead program.
- OTC market listing presents liquidity and regulatory challenges.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
MSCLF Latest News
No recent news available for MSCLF.
MSCLF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MSCLF.
Price Targets
Wall Street price target analysis for MSCLF.
MSCLF MoonshotScore
What does this score mean?
The MoonshotScore rates MSCLF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Francis Gleeson
CEO
Francis Gleeson serves as the CEO of Satellos Bioscience Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held various leadership positions in research and development, business development, and commercialization. Gleeson's expertise spans drug discovery, clinical development, and regulatory affairs. He is responsible for managing 14 employees at Satellos Bioscience Inc.
Track Record: Under Francis Gleeson's leadership, Satellos Bioscience Inc. has focused on developing its lead program targeting muscle stem cell polarity. Key milestones include advancing the program through preclinical studies and preparing for clinical trials. Gleeson has also overseen the company's efforts to secure funding and establish strategic partnerships. His strategic decisions have shaped the company's direction in the regenerative medicine space.
MSCLF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Satellos Bioscience Inc. may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance. Trading on the OTC Other tier carries higher risks compared to exchanges like NYSE or NASDAQ, which have stricter listing standards and regulatory oversight. It is essential for investors to conduct thorough due diligence before investing in companies on this tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Higher risk of fraud or mismanagement compared to listed companies.
- Lower liquidity and wider bid-ask spreads.
- Greater price volatility and potential for manipulation.
- Limited regulatory oversight and investor protection.
- Verify the company's management team and their track record.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Check for any regulatory filings or legal proceedings.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Focus on regenerative medicine and a specific therapeutic area.
- Management team with experience in biotechnology.
- Development of a lead program targeting muscle stem cell polarity.
- Incorporation in Canada and headquarters in Toronto.
- Presence on financial data platforms, even with limited information.
Satellos Bioscience Inc. Healthcare Stock: Key Questions Answered
What does Satellos Bioscience Inc. do?
Satellos Bioscience Inc. is a regenerative medicine company focused on developing therapeutics for degenerative muscle diseases. Their primary focus is on correcting muscle stem cell polarity to restore the body's natural muscle repair process. The company's lead program is an oral therapeutic drug designed to address this mechanism. By targeting the root cause of muscle degeneration, Satellos aims to provide innovative solutions for patients suffering from these debilitating conditions. Their approach leverages the body's innate regenerative capabilities to promote muscle repair and regeneration.
What are the main risks for MSCLF?
The main risks for Satellos Bioscience Inc. include the inherent uncertainties of drug development, such as clinical trial failures and regulatory hurdles. Competition from larger biotechnology and pharmaceutical companies poses a significant threat. The company's limited financial resources and reliance on external funding create financial risks. Additionally, the OTC market listing presents liquidity and regulatory challenges. Investors should carefully consider these risks before investing in MSCLF.
What are the key factors to evaluate for MSCLF?
Satellos Bioscience Inc. (MSCLF) holds an AI score of 52/100 (moderate). Not financial advice.
How frequently does MSCLF data refresh on this page?
MSCLF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MSCLF's recent stock price performance?
Satellos Bioscience Inc. (MSCLF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel approach to treating degenerative muscle diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MSCLF overvalued or undervalued right now?
Valuing Satellos Bioscience Inc. (MSCLF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MSCLF?
Before investing in Satellos Bioscience Inc. (MSCLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding MSCLF to a portfolio?
Key strength of Satellos Bioscience Inc. (MSCLF): Novel approach to treating degenerative muscle diseases. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available due to OTC listing.
- AI analysis pending.